264 related articles for article (PubMed ID: 31109190)
1. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.
Torbicki A; Bacchi M; Delcroix M; Farber HW; Ghofrani HA; Hennessy B; Jansa P; Mehta S; Perchenet L; Pulido T; Rosenberg D; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Wei LJ; Channick R; Benza R
Circ Cardiovasc Qual Outcomes; 2019 May; 12(5):e005095. PubMed ID: 31109190
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
Souza R; Delcroix M; Galié N; Jansa P; Mehta S; Pulido T; Rubin L; Sastry BKS; Simonneau G; Sitbon O; Torbicki A; Boyanova N; Chamitava L; Stein C; Channick RN
Adv Ther; 2022 Sep; 39(9):4374-4390. PubMed ID: 35819570
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
4. Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study.
Di Scala L; Bacchi M; Bayer B; Turricchia S
Adv Ther; 2022 Sep; 39(9):4346-4358. PubMed ID: 35917059
[TBL] [Abstract][Full Text] [Related]
5. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
Jansa P; Pulido T
Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacies of selective vasodilators in pulmonary arterial hypertension: a comprehensive comparison using a spontaneous reporting database.
Suzuki K; Yagi T; Kawakami J
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4981-4992. PubMed ID: 38180559
[TBL] [Abstract][Full Text] [Related]
7. Macitentan: A Review in Pulmonary Arterial Hypertension.
Keating GM
Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
[TBL] [Abstract][Full Text] [Related]
8. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
Belge C; Delcroix M
Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
[TBL] [Abstract][Full Text] [Related]
10. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.
Mehta S; Sastry BKS; Souza R; Torbicki A; Ghofrani HA; Channick RN; Delcroix M; Pulido T; Simonneau G; Wlodarczyk J; Rubin LJ; Jansa P; Hunsche E; Galiè N; Perchenet L; Sitbon O
Chest; 2017 Jan; 151(1):106-118. PubMed ID: 27671974
[TBL] [Abstract][Full Text] [Related]
11. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
Krause A; Zisowsky J; Dingemanse J
Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
[TBL] [Abstract][Full Text] [Related]
12. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.
Simonneau G; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Le Brun FO; Mehta S; Perchenet L; Pulido T; Sastry BK; Sitbon O; Souza R; Torbicki A; Rubin LJ
Eur Respir J; 2015 Dec; 46(6):1711-20. PubMed ID: 26493786
[TBL] [Abstract][Full Text] [Related]
13. Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
Channick RN; Delcroix M; Ghofrani HA; Hunsche E; Jansa P; Le Brun FO; Mehta S; Pulido T; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A; Galiè N
JACC Heart Fail; 2015 Jan; 3(1):1-8. PubMed ID: 25457902
[TBL] [Abstract][Full Text] [Related]
14. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
Petrovič M; Locatelli I
Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
[No Abstract] [Full Text] [Related]
16. Macitentan for the treatment of pulmonary arterial hypertension.
DuBrock HM; Channick RN
Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
Gaine S; Sitbon O; Channick RN; Chin KM; Sauter R; Galiè N; Hoeper MM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Tapson V; Ghofrani HA; Lang I
Chest; 2021 Jul; 160(1):277-286. PubMed ID: 33545163
[TBL] [Abstract][Full Text] [Related]
18. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
19. Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials.
Scott JV; Garnett CE; Kanwar MK; Stockbridge NL; Benza RL
Am J Respir Crit Care Med; 2021 Mar; 203(6):726-736. PubMed ID: 32937078
[No Abstract] [Full Text] [Related]
20. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
Badagliacca R; D'Alto M; Ghio S; Argiento P; Bellomo V; Brunetti ND; Casu G; Confalonieri M; Corda M; Correale M; D'Agostino C; De Michele L; Galgano G; Greco A; Lombardi C; Manzi G; Mercurio V; Mulè M; Paciocco G; Papa S; Romeo E; Scelsi L; Stolfo D; Vitulo P; Naeije R; Vizza CD
Am J Respir Crit Care Med; 2021 Feb; 203(4):484-492. PubMed ID: 32857597
[No Abstract] [Full Text] [Related]
[Next] [New Search]
